Benign Essential Blepharospasm--There Is More to It Than Just Blinking

Update item information
Title Benign Essential Blepharospasm--There Is More to It Than Just Blinking
Creator Kathleen B. Digre, MD
Affiliation Professor of Neurology and Ophthalmology, Director of Neuro-Ophthalmology, John A. Moran Eye Center, University of Utah School of Medicine; Departments of Neurology (KIL, MMM), Neurosurgery (RCR), and Radiation Oncology (JKR), University of Washington, Seattle, Washington; and Neuro-Ophthalmic Consultants Northwest (SRH), Swedish Medical Center, Seattle, Washington
Subject Animals; Blepharospasm; Blinking; Disease Models, Animal; Humans
Abstract High-grade (World Health Organization [WHO] Grade II and III) meningiomas constitute a minority of all meningioma cases but are associated with significant morbidity and mortality, due to more aggressive tumor behavior and a tendency to recur despite standard therapy with resection and radiotherapy. They display a higher degree of vascularity than WHO Grade I meningiomas and produce angiogenic and growth factors, including vascular endothelial growth factor (VEGF). Bevacizumab, a humanized monoclonal antibody against VEGF-A, has been used in the treatment of recurrent or progressive meningiomas resistant to standard therapy. We report a patient with a recurrent left frontotemporal meningioma and associated-vision loss who experienced substantial visual field recovery after 3 cycles of bevacizumab. In addition, we provide a review of the literature regarding the efficacy of bevacizumab in the treatment of recurrent meningiomas.
OCR Text Show
Publisher Lippincott, Williams & Wilkins
Date 2015-12
Type Text
Language eng
Rights Management © North American Neuro-Ophthalmology Society
Publication Type Journal Article
ARK ark:/87278/s6ff7mvb
Setname ehsl_novel_jno
Date Created 2017-09-14
Date Modified 2020-03-11
ID 1276426
Reference URL
Back to Search Results